Trial Profile
Special exception use of 5-azacytidine in myelodysplastic syndromes (National Cancer Institute, Bethesda)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2005
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 26 Oct 2005 New trial record.